Takumi Kawabe

USPTO Granted Patents = 17 (Patent Applications = 3)

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 2.3

ph-index = 3

Forward Citations = 31(Granted Patents)

Location History:

Nagoya, JP (2005)
Numazu, JP (2006 - 2015)
Shizuoka, JP (2018)

Company Filing History:

Takeda Pharmaceutical Company Limited

patents

1 out of 4

General Incorporated Association Pharma Valley Project Supporting Organization

patents

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12239714 - Phosphatidylserine-binding conjugates (2025-03-04),

2. 12209079 - IDO/TDO inhibitor (2025-01-28),

3. 10149887 - Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment (2018-12-11),

4. 9221872 - Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations (2015-12-29),

5. 8415357 - Compounds with anti-cancer activity (2013-04-09),

6. 8084454 - Compounds with anti-cancer activity (2011-12-27),

7. 7851592 - Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents (2010-12-14),

8. 7652042 - Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments (2010-01-26),

9. 7629364 - Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments (2009-12-08),

10. 7479484 - Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity (2009-01-20),

11. 7476657 - Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments (2009-01-13),

12. 7407985 - Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments (2008-08-05),

13. 7358046 - Sensitivity test to predict efficacy of anti-cancer therapies (2008-04-15),

14. 7125842 - Anti-fungal compounds and methods of use (2006-10-24),

15. 7030111 - Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments (2006-04-18),

Title: The Innovative Contributions of Takumi Kawabe

Introduction

Takumi Kawabe is a prominent inventor based in Numazu, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 17 patents. His work focuses on developing innovative therapeutic agents for various diseases and disorders.

Latest Patents

Among his latest patents are the phosphatidylserine-binding conjugates, which are designed to bind phosphatidylserine (PS) and toll-like receptors (TLRs). These conjugates have potential applications in treating selected diseases, including cancer. Another notable patent is for an IDO/TDO inhibitor, which is a compound that can serve as a therapeutic agent for a range of conditions such as tumors, infectious diseases, neurodegenerative disorders, and autoimmune diseases.

Career Highlights

Throughout his career, Takumi Kawabe has worked with notable companies, including Canbas Co., Ltd. and Takeda Pharmaceutical Company Limited. His expertise in the pharmaceutical industry has allowed him to contribute to the development of groundbreaking treatments.

Collaborations

Takumi has collaborated with esteemed colleagues, including Hidetaka Kobayashi and Takuji Sato. These partnerships have further enhanced his innovative work in the field.

Conclusion

Takumi Kawabe's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical science. His patents reflect a dedication to improving health outcomes for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.